Payment overview · 2025
General Payments
$117.38
6 reported records · 6 companies
Healthcare provider profile · identity verified
Paul James Simpson, DO
Allopathic & Osteopathic Physicians|Family Medicine · THREE RIVERS, MI · NPI 1043530942
Verified facts
What the public records show
CMS Open Payments records show Paul James Simpson, DO received $117.38 in general payments during 2025 across 6 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $25.45 | 21.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.83 | 20.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.70 | 17.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.53 | 15.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.93 | 12.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.94 | 11.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.38 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 143 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 111 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 35 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
143 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 719 | 217 |
| Levothyroxine Sodium | Levothyroxine Sodium | 512 | 129 |
| Lisinopril | Lisinopril | 446 | 137 |
| Omeprazole | Omeprazole | 327 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 307 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 89 |
| Losartan Potassium | Losartan Potassium | 295 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 273 | 74 |
| Gabapentin | Gabapentin | 271 | 73 |
| Metformin Hcl Er | Metformin Hcl | 251 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 226 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 206 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 83 |
| Simvastatin | Simvastatin | 163 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 40 |
| Eliquis | Apixaban | 143 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 59 |
| Furosemide | Furosemide | 143 | 47 |
| Metformin Hcl | Metformin Hcl | 138 | 36 |
| Trazodone Hcl | Trazodone Hcl | 138 | 42 |
| Ezetimibe | Ezetimibe | 127 | 43 |
| Montelukast Sodium | Montelukast Sodium | 118 | 36 |
| Tramadol Hcl | Tramadol Hcl | 114 | 26 |
| Allopurinol | Allopurinol | 112 | 34 |
| Jardiance | Empagliflozin | 111 | 35 |
| Carvedilol | Carvedilol | 107 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 32 |
| Finasteride | Finasteride | 97 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 30 |
| Spironolactone | Spironolactone | 89 | 21 |
| Ozempic | Semaglutide | 88 | 20 |
| Alendronate Sodium | Alendronate Sodium | 79 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 24 |
| Potassium Chloride | Potassium Chloride | 79 | 24 |
| Alprazolam | Alprazolam | 72 | 21 |
| Donepezil Hcl | Donepezil Hcl | 70 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 14 |
| Bupropion Xl | Bupropion Hcl | 68 | 18 |
| Sertraline Hcl | Sertraline Hcl | 67 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 16 |
| Mounjaro | Tirzepatide | 61 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 16 |
| Famotidine | Famotidine | 59 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 58 | 17 |
| Pregabalin | Pregabalin | 55 | 11 |
| Atenolol | Atenolol | 54 | 18 |
| Xarelto | Rivaroxaban | 54 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 19 |
| Prednisone | Prednisone | 53 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 17 |
| Trulicity | Dulaglutide | 50 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 18 |
| Myrbetriq | Mirabegron | 49 | 16 |
| Glipizide Er | Glipizide | 47 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | suppressed |
| Celecoxib | Celecoxib | 44 | 13 |
| Buspirone Hcl | Buspirone Hcl | 43 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 13 |
| Cephalexin | Cephalexin | 39 | 24 |
| Meloxicam | Meloxicam | 39 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Torsemide | Torsemide | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 18 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 12 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Tegretol Xr | Carbamazepine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.38 · 6 records | E.R. Squibb & Sons, L.L.C. | ELIQUIS, GARDASIL 9, JARDIANCE, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error